IRIDEX Osake

IRIDEX EV/FCF

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä IRIDEX (IRIX) 26.7.2026 päivämäärällä on −7,53. Edellisenä vuonna EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) oli −2,83 — muutos 166,21 % (matalampi).

EV/FCF

−7,53

YoY

166,21%

Viimeksi päivitetty:

EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä IRIDEX on 2026 −7,53 . EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) yhtiöstä IRIDEX oli 2025 −2,83 . Se laskee 166,21% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

IRIDEX Osakeanalyysi

Mitä IRIDEX tekee? IRIDEX Corp is a global medical technology company that specializes in the development, manufacturing, marketing, and distribution of innovative laser-based medical devices and services. The company was originally founded in 1989 and is headquartered in Mountain View, California. IRIDEX's business model is divided into various divisions, each serving different markets. The divisions include ophthalmology, otolaryngology (ENT), gynecology and urology, as well as scientific research. The company offers a wide range of high-tech laser systems that can be used to treat various conditions, such as retinal diseases, glaucoma, nasal and throat disorders, gynecological and urological conditions, and other medical applications. One of the most well-known divisions of IRIDEX is ophthalmology, which offers a wide range of laser systems for the treatment of retinal diseases. These retinal diseases include diabetic retinopathy, retinal edema, age-related macular degeneration, and retinal detachment. The company also has a high-tech system called Cyclo G6TM, which is used for the treatment of glaucoma. This system can also be used in conjunction with other devices, such as ultrasound systems, for optimized clinical effectiveness. The ENT division offers laser systems for the treatment of nasal and throat disorders, such as snoring, polyps, stenosis, and tumors. The range of laser systems varies from simple systems to advanced systems that can be connected to a flexible endoscope for more precise treatment. IRIDEX's gynecology and urology division offers laser systems for various applications, such as urinary incontinence, bladder problems, tumor removal, prostate tissue removal, and medical treatments to improve sexual function. Laser systems can also be used in combination with other medical devices, such as ultrasound systems. The company places great emphasis on scientific research and development to create and introduce innovative technologies to the market. Therefore, IRIDEX collaborates closely with various research institutes, universities, and medical professionals to further develop its technological advances. The company is also committed to providing comprehensive training and support to its customers to ensure that they use the devices safely and effectively. Overall, IRIDEX Corp has established itself as an innovative and powerful multinational company in the field of medical technology. The company is constantly striving to expand its range of products and services and impress its customers with its high-quality solutions. IRIDEX is confident that it will continue to play a significant role in the medical technology industry in the future. IRIDEX on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset IRIDEX osakkeesta

Yhtiön IRIDEX EV/FCF (Yrityksen arvo suhteessa vapaaseen kassavirtaan) on −7,53 vuonna 2026.

Access this data via the Eulerpool API

Arvostus — IRIDEX

Kaikki tunnusluvut — IRIDEX